PMID- 17106197
OWN - NLM
STAT- MEDLINE
DCOM- 20080110
LR  - 20220310
IS  - 1421-9751 (Electronic)
IS  - 0008-6312 (Linking)
VI  - 108
IP  - 4
DP  - 2007
TI  - Effects of thalidomide treatment in heart failure patients.
PG  - 237-42
AB  - BACKGROUND: Several studies have reported a direct association between elevated 
      plasma levels of inflammatory cytokines and worse functional class (New York 
      Heart Association [NYHA]) and cardiac function, measured as left ventricular 
      ejection fraction (LVEF). Thalidomide has recently shown to improve LVEF in 
      chronic heart failure patients, accompanied by a marked decrease in plasma levels 
      of tumor necrosis factor alpha (TNF-alpha). METHODS: In a randomized prospective 
      open label study of men and women with heart failure (HF) due to ischemic and 
      non-ischemic cardiomyopathy who had systolic dysfunction (LVEF <40%) and NHYA 
      classification, functional classes II and III were assigned to control (without 
      thalidomide, 60 patients) or thalidomide group (20 patients). The initial dose of 
      thalidomide was 100 mg once a day, and it was increased to 100 mg twice a day 
      after a period of 10 days, if the prior dosage was well-tolerated. Demographic 
      characteristics, etiology of HF, prior myocardial infarction, co-morbidities 
      associated were registered and laboratory routine test, TNF-alpha serum levels, 
      and echocardiogram were obtained at the beginning and after 6 months of 
      follow-up. RESULTS: Clinical status (NYHA) at the end of the follow-up period, 
      improved moderately in both groups. TNF-alpha levels were initially of 5.88 +/- 
      0.9 and 6.49 +/- 1.82 vs. 6.32 +/- 1.6 and 7.94 +/- 3.8 pg/ml during follow-up, 
      for thalidomide and control groups, respectively. There were non-significant 
      differences in echocardiography variables. CONCLUSION: In conclusion, although 
      there is a large amount of information supporting a direct relationship between 
      TNF-alpha and worsening of symptoms and prognosis in patients with HF and 
      recently, the beneficial effect on thalidomide treatment has been suggested, 
      these preliminary observations should be confirmed in a larger prospective study, 
      specially trying to clarify the action mechanisms.
CI  - (c) 2007 S. Karger AG, Basel.
FAU - Orea-Tejeda, Arturo
AU  - Orea-Tejeda A
AD  - Heart Failure Clinic, Mexico City, Mexico.
FAU - Arrieta-Rodriguez, Oscar
AU  - Arrieta-Rodriguez O
FAU - Castillo-Martinez, Lilia
AU  - Castillo-Martinez L
FAU - Rodriguez-Reyna, Tatiana
AU  - Rodriguez-Reyna T
FAU - Asensio-Lafuente, Enrique
AU  - Asensio-Lafuente E
FAU - Granados-Arriola, Julio
AU  - Granados-Arriola J
FAU - Dorantes-Garcia, Joel
AU  - Dorantes-Garcia J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20061109
PL  - Switzerland
TA  - Cardiology
JT  - Cardiology
JID - 1266406
RN  - 0 (Biomarkers)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 4Z8R6ORS6L (Thalidomide)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Cardiovascular Agents/*therapeutic use
MH  - Female
MH  - Heart Failure/blood/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Thalidomide/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/blood
EDAT- 2006/11/16 09:00
MHDA- 2008/01/11 09:00
CRDT- 2006/11/16 09:00
PHST- 2006/02/06 00:00 [received]
PHST- 2006/07/30 00:00 [accepted]
PHST- 2006/11/16 09:00 [pubmed]
PHST- 2008/01/11 09:00 [medline]
PHST- 2006/11/16 09:00 [entrez]
AID - 96829 [pii]
AID - 10.1159/000096829 [doi]
PST - ppublish
SO  - Cardiology. 2007;108(4):237-42. doi: 10.1159/000096829. Epub 2006 Nov 9.